Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study

Abstract

A once-daily combination product of irbesartan and atorvastatin provided an effective, safe, and more compliable treatment for patients with coexisting hypertension and hyperlipidemia. ClinicalTrials.gov identifier: NCT01442987.

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea

“…Currently, a number of statin‐ARB FDC therapies are commercially available. The efficacy and safety of statin‐ARB FDC therapies were proven in previous studies . FDC therapies were also suggested as an appealing option for patients who require multiple medications, such as patients with CHD, due to their acceptability and cost‐effectiveness .…”

“…The efficacy and safety of statin-ARB FDC therapies were proven in previous studies. 44,45 FDC therapies were also suggested as an appealing option for patients who require multiple medications, such as patients with CHD, due to their acceptability and cost-effectiveness. 46 Thus it is likely that the availability of statin-ARB FDC therapies contributed to the reduced incidence of MACCE in patients in the statin-ARB cohort.…”

Fixed‐dose combinations of lipid‐lowering and antihypertensive agents: The way forward?

“…5,6 Given the large number of patients who have both hypertension and hypercholesterolemia as well as the increased cardiovascular risk that results from their coexistence, several studies evaluated the safety and efficacy of fixed-dose combinations of atorvastatin and up to three different antihypertensive agents. [7][8][9][10] All these studies showed that fixed-dose combinations result in similar reductions in blood pressure (BP) and LDL-C levels compared with separate pill regimens. [7][8][9][10] In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents.…”

“…[7][8][9][10] All these studies showed that fixed-dose combinations result in similar reductions in blood pressure (BP) and LDL-C levels compared with separate pill regimens. [7][8][9][10] In contrast, there are limited data regarding the effects on BP and LDL-C levels of fixed-dose combinations of rosuvastatin and antihypertensive agents. [11][12][13] Since rosuvastatin induces the largest reductions in LDL-C levels among statins, including this agent in a fixed-dose combination with antihypertensive agents might represent a useful tool in achieving LDL-C targets, particularly in high-risk patients.…”

“…15 The findings of the study by Kim et al further strengthen the results of previous studies, which showed that fixed-dose combination of statins and antihypertensive agents is similarly effective and safe with monotherapy. [7][8][9][10][11][12][13]15 It is well-established that despite the availability of several effective and safe classes of antihypertensive agents, less than one third of patients with treated hypertension have controlled blood pressure. 3 Accordingly, among patients with hypercholesterolemia who are receiving lipid-lowering treatment, LDL-C targets are achieved in approximately two thirds of patients.…”